A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
Completed · Phase 3 · NCT03952559
Conditions: Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $53
- U.S. investigators named
- 2
- Sites paid
- 1
- Planned or actual enrollment
- 516
About the trial
- Sponsor
- Eli Lilly and Company (with Incyte Corporation)
- Tested
- Baricitinib (drug), Placebo (drug), Topical corticosteroid (drug)
- Dates
- Started 2019-05-24; completion 2026-05-22
- Results posted
- Yes
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
From ClinicalTrials.gov, last updated 2026-08-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $53 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nicholas J. Kamp, M.D. Cardiology · Indianapolis, IN
- Zackary D. Goff, M.D. Cardiology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.